Xilis

Xilis is developing next generation MicroOrganoSphereTM technologies to guide precision therapy for cancer patients and accelerate drug discovery. Xilis is developing next-generation technologies to guide precision therapy for cancer patients and accelerate drug discovery and development. Xilis’ Precision Oncology Platform enables clinicians to make timely treatment decisions by predicting patient treatment response and guiding optimal therapeutic options. The Xilis Precision Oncology Platform and Xilis Response ScoreTM can guide prioritized treatment decisions for oncologists and ensure patients get the right drug at the right time. Cancer is the second leading cause of death in the U.S. Our breakthrough platform provides cost-effective, high-throughput drug candidate screening, pre-clinical assessment of immuno-oncology drugs, personalized assays to determine patient eligibility for clinical trials, and companion diagnostics to guide patients to newly developed treatments.